Inflammation and hypoxia are known to promote the metastatic progression of tumours. The CCAAT/enhancerbinding protein-d (C/EBPd, CEBPD) is an inflammatory response gene and candidate tumour suppressor, but its physiological role in tumourigenesis in vivo is unknown. Here, we demonstrate a tumour suppressor function of C/EBPd using transgenic mice overexpressing the Neu/Her2/ERBB2 proto-oncogene in the mammary gland. Unexpectedly, this study also revealed that C/EBPd is necessary for efficient tumour metastasis. We show that C/EBPd is induced by hypoxia in tumours in vivo and in breast tumour cells in vitro, and that C/EBPd-deficient cells exhibit reduced glycolytic metabolism and cell viability under hypoxia. C/EBPd supports CXCR4 expression. On the other hand, C/EBPd directly inhibits expression of the tumour suppressor F-box and WD repeat-domain containing 7 gene (FBXW7, FBW7, AGO, Cdc4), encoding an F-box protein that promotes degradation of the mammalian target of rapamycin (mTOR). Consequently, C/EBPd enhances mTOR/AKT/S6K1 signalling and augments translation and activity of hypoxia-inducible factor-1a (HIF-1a), which is necessary for hypoxia adaptation. This work provides new insight into the mechanisms by which metastasis-promoting signals are induced specifically under hypoxia.
Introduction
Aerobic life depends on oxygen, and suboptimal levels of O 2 trigger cellular responses to cope transiently with hypoxia. These include decrease in oxygen consumption through metabolic adaptation such as reduced mitochondrial activity and enhanced glycolysis, and increase in oxygen delivery through induced angiogenesis. Similar mechanisms are also adopted by tumour cells even under normoxia, which is one reason why hypoxia is thought to promote tumourigenesis (Weidemann and Johnson, 2008) . Most of the responses to hypoxia are governed by heterodimeric transcription factors called hypoxia-inducible factors (HIFs). HIFs consist of two subunits: a constitutive b-subunit and one of three oxygendependently regulated a-subunits. The most studied hypoxiainducible transcription factor is HIF-1a. Collectively, most data point to a role of HIF-1a in promoting tumourigenesis (Zhou et al, 2006; Yee Koh et al, 2008; Semenza, 2010) . Under normoxia, the HIF-1a protein is hydroxylated by ubiquitous iron-and O 2 -dependent prolyl hydroxylases (PHDs) that target HIF-1a for proteasomal degradation. Hence, reduced levels of oxygen, as found in solid tumours, stabilize the HIF1a subunit because of inactivation of PHDs (Wei and Yu, 2007) . However, oncogenes and growth factors also contribute to upregulation of HIF-1a expression, in part through stimulation of translation by a PI3K/AKT/mTOR-dependent pathway (Semenza, 2003; Yee Koh et al, 2008) . In addition to supporting hypoxia adaptation, HIF-1a contributes to cell migration and metastasis. Thus, hypoxia in tumours promotes selection of tumour cells with aggressive phenotype (Zhou et al, 2006) . Mice deficient in mammary epithelial expression of HIF-1a exhibit reduced tumour growth and significantly fewer lung metastases (Liao et al, 2007) .
HIF-1a expression and activity have also been documented in the immune system and injured tissue in which it participates in inflammatory responses (Frede et al, 2007; Zinkernagel et al, 2007) . The transcription factor CCAAT/ enhancer-binding protein-d (C/EBPd) is another inflammatory response gene that is induced by bacterial lipopolysaccharide in most cell types and tissues, and amplifies inflammatory signalling pathways (Ramji and Foka, 2002; Litvak et al, 2009) . In this regard, C/EBPd expression and function parallels that of HIF-1a. However, in contrast to HIF1a, C/EBPd has tumour suppressor-like activities. Loss of C/EBPd causes genomic instability in mouse embryo fibroblasts (MEFs) in vitro . C/EBPd promotes apoptosis during involution of the mouse mammary gland (Thangaraju et al, 2005) and inhibits the growth of human cell lines from several tumour types including breast in vitro (Gery et al, 2005; Agrawal et al, 2007; Pawar et al, 2010) . In support of a tumour suppressor function in vivo, C/EBPd protein expression correlates with low-grade histology and disease-free survival of meningioma patients (Barresi et al, 2009) , and C/EBPd was among a 70-gene signature predicting better survival of breast cancer patients (Naderi et al, 2007) . Furthermore, the C/EBPd gene was found to be methylated in a significant number of acute myelomonocytic leukaemia, cervical and hepatocellular carcinomas and a subset of breast tumours (Gery et al, 2005; Tang et al, 2005; Agrawal et al, 2007; Ko et al, 2008) , and its expression is downregulated with breast tumour progression (Porter et al, 2001) . Although C/EBPd contains a classical transcription activation domain, it can act both as an activator and an inhibitor of gene promoters (Lacorte et al, 1997; Okazaki et al, 2002; Ramji and Foka, 2002; Wang et al, 2006; Lai et al, 2008; Turgeon et al, 2008) .
In this study, we have used transgenic technology to assess the role of C/EBPd in mammary tumourigenesis in vivo. This approach confirmed a tumour suppressor function of C/EBPd while also uncovering an unexpected pro-metastatic activity. We found that C/EBPd supports HIF-1a translation through inhibition of F-box and WD repeat-domain containing 7 gene (FBXW7) expression and, as a result, stabilization of the mammalian target of rapamycin (mTOR) protein. These data reveal a novel role for C/EBPd in integration of hypoxia and inflammatory responses to promote tumour metastasis.
Results

Loss of C/EBPd increases mammary tumour multiplicity and decreases lung metastasis
To assess the potential tumour suppressor function of C/EBPd in vivo, we used MMTV-c-Neu transgenic mice. These mice express rat tyrosine kinase receptor Neu (ERBB2/HER2) specifically in mammary epithelial cells to mimic the overexpression of ERBB2 seen in over 30% of human breast cancers (Guy et al, 1992 ). This mouse model generates stochastic, slow-onset mammary tumours in female mice before the age of 1 year (Guy et al, 1992) . In mice with a germ-line deletion of the C/EBPd gene (Sterneck et al, 1998) , tumour multiplicity was significantly increased ( Figure 1A ). C/EBPd-deficient (knock out, KO) mice bore 50% more tumours than wild-type (WT) or heterozygous controls at the study end point, which was defined by the size of the primary tumour. Survival based on study end point was similar between genotypes (Supplementary Figure S1) , and the tumours of different groups of mice were histologically and morphologically comparable and typical of Neu morphology (Guy et al, 1992) . Given that the study end point was defined by the size of the primary tumour, this implies that loss of C/EBPd does not affect the growth rate of the tumours. Rather, more tumours are initiated in the mutant mice with or during the time of primary tumour growth. Thus, we infer that C/EBPd may inhibit the probability of tumour initiation and/or the number of target cells. Regardless of the mechanism, these data represent the first animal model to show that C/EBPd acts as a tumour suppressor.
Mammary tumours of this transgenic model metastasize to the lung (Guy et al, 1992) . For metastasis-bearing mice, the average metastatic burden was 0.4% of the total lung area and not affected by genotype (P ¼ 0.1455, by two-sample t-test; n ¼ 8 KO, 16 WT mice) . Surprisingly, C/EBPd KO animals were less likely to develop lung metastases, with only 40% of the C/EBPd-mutant mice harbouring metastases, compared with 80% of the WT group ( Figure 1B) . As, in a clinical setting, metastases are the primary cause of death from breast cancer, a 50% reduction or delay in the incidence of metastasis is an important outcome. Collectively, these results demonstrate that C/EBPd has dual activity in mammary tumourigenesis: on the one hand, C/EBPd inhibits primary tumour development and on the other hand, it augments metastasis formation. C/EBPd is required for hypoxic HIF-1a accumulation and hypoxia adaptation As previous reports documented reduced C/EBPd mRNA expression with progression of breast tumourigenesis (Porter et al, 2001) , we first asked when and where C/EBPd was expressed. Immunohistochemistry of mature nulliparous mouse mammary glands, which-in contrast to human breast-contain mostly ductal epithelium, at different stages of the oestrous cycle revealed low levels of C/EBPd protein in very few epithelial cells (data not shown). However, analysis of tumour tissue revealed significant, but regionally restricted, expression of C/EBPd within the tumours. These regions often surrounded necrotic centres of the tumours typical of hypoxic regions. Indeed, analysis of parallel sections revealed that C/EBPd expression correlated with hypoxic areas, which were visualized by immunohistochemistry of pimonidazole-derived protein modifications ( Figure 1C ). Because tumour hypoxia is strongly associated with increased metastasis formation (Sullivan and Graham, 2007) and the pro-metastatic activity of C/EBPd is shared with the HIF-1a protein (Liao et al, 2007) , we next examined whether C/EBPd modulated the expression of HIF-1a. In a subset of C/EBPd-expressing tumour areas, we could also detect expression of HIF-1a (data not shown). For quantitative analysis of HIF-1a expression, we exposed isolated primary mammary tumour cells to 1% oxygen or the iron chelator desferrioxamine (DFX), which inhibits PHD enzymes and thereby stabilizes HIF-a proteins (Hirsila et al, 2005) . While HIF-1a protein was highly induced in WT primary tumour cells under these treatments, cells lacking C/EBPd exhibited significantly reduced HIF-1a protein levels ( Figure 1D ). Expression of the HIF-1b protein subunit is not regulated by hypoxia (Wei and Yu, 2007) , and its levels were not affected in either cell type. This experiment confirmed that C/EBPd expression was induced in WT cells by hypoxia or DFX ( Figure 1D ). We also examined expression of the HIF-1 target gene CXCR4, a chemokine receptor, which strongly promotes metastatic progression of tumours (Gelmini et al, 2008) . Indeed, CXCR4 protein expression was induced in WT, but not in KO, primary tumour cells ( Figure 1D ). Reduced CXCR4 expression was consistent with reduced HIF-1a levels in C/EBPd-deficient cells. These data reveal a novel function for C/EBPd in amplifying HIF-1a expression and HIF-1 activity, which is consistent with the pro-metastatic activity of both these factors. The profound absence of CXCR4 expression in C/EBPd-deficient cells even under normoxia led us to examine whether this gene was directly regulated by C/EBPd. Indeed, chromatin immunoprecipitation (ChIP) and RNA analyses in MCF-7 cells support a direct role for C/EBPd in CXCR4 expression (Supplementary Figure S2) , which may contribute to its pro-metastatic function.
Because of the hypoxia-induced expression of C/EBPd, we further focused on its role in the HIF-1 pathway.
Because HIF-1 promotes a switch to glycolytic metabolism to maintain energy homeostasis and survival under hypoxia (Semenza, 2010) , we assessed the role of C/EBPd in the glycolytic response. In primary WT tumour cells in vitro, hypoxia stimulated the uptake of glucose and the release of lactate ( Figure 1E ). Loss of C/EBPd significantly blunted both these responses ( Figure 1E ). Having demonstrated that C/EBPd was required for glycolytic metabolism, we further investigated the role of C/EBPd in cell survival. As shown in Figure 1F , C/EBPd KO primary tumour cells were more sensitive to hypoxia than WT cells, indicating that C/EBPd promotes survival of tumour cells under hypoxia.
To assess whether the role of C/EBPd in hypoxia response is also relevant for human cells, we examined the effect of acute C/EBPd depletion on HIF-1a protein accumulation under hypoxia or in response to the chemical HIF-1a stabilizers DFX or cobalt chloride. In the MCF-7 breast adenocarcinoma cell line, all three treatments induced not only HIF-1a but also C/EBPd protein expression (Figure 2A ). RNAimediated depletion of endogenous C/EBPd protein reduced HIF-1a protein expression under hypoxia and HIF-1a-stabilizing conditions. These results demonstrate that induction of the C/EBPd protein under hypoxia also occurs in human breast tumour cells, and that it is necessary for efficient expression of the HIF-1a protein and HIF-1 activity.
Interestingly, while C/EBPd is downregulated in many cancers (see Introduction), analysis of publicly available expression data at http://www.ONCOMINE.org showed that C/EBPd is overexpressed in glioblastoma (data not shown). Advanced glioblastoma is characterized by significant tumour hypoxia associated with highly invasive properties dependent on HIF-1 (Kaur et al, 2005) . Indeed, we found that the human glioblastoma cell line U251 expressed readily detectable basal levels of C/EBPd that were not further induced by DFX ( Figure 2B ). As seen in MCF-7 cells (Figure 2A ), RNAi-mediated knockdown of C/EBPd in U251 cells significantly reduced HIF-1a protein levels in response to DFX ( Figure 2B ). The U251-HRE cell line used here contains a HIF-dependent luciferase reporter gene that is induced by hypoxia (Rapisarda et al, 2002) . In accordance with reduced HIF-1a protein levels, knockdown of C/EBPd diminished HIF-dependent reporter gene activity in response to DFX ( Figure 2C ). Taken together, these data demonstrate that C/EBPd is a hypoxia response gene in certain mouse and human tumour cells. Under all conditions tested, C/EBPd was required for efficient expression of the HIF-1a protein.
Through analysis and reconstitution of MEFs derived from C/EBPd-null mutant mice, we could demonstrate the causal relationship of C/EBPd and HIF-1a expression, and that the reduced HIF-1a protein levels in C/EBPd-null cells significantly 
Reduced HIF-1a expression correlates with impaired AKT signalling
Because C/EBPd promoted HIF-1a expression in primary tumour cells, MEFs, glioblastoma and breast tumour cells, we chose KO MEFs to study the mechanism by which C/EBPd augments HIF-1a expression. We found that C/EBPd did not affect HIF-1a mRNA expression or protein stability (Supplementary Figure S4) , suggesting that C/EBPd may promote HIF-1a translation. Inflammatory signals, cytokines and growth factors such as insulin promote HIF-1a translation through AKT (PKB) signalling (Semenza, 2003; Yee Koh et al, 2008) . The serine/threonine kinase AKT is activated by phosphorylation at Ser473 by mTOR/rictor/LST8 of the mTORC2 complex. AKT then activates its downstream effectors including the mTORC1 complex consisting of mTOR/ raptor/PRAS40, which stimulates translation through phosphorylation of the ribosomal S6 kinase 1 (S6K1) and of 4E-BP1, a repressor of the eIF4E translation initiation factor (Dann et al, 2007) . To address the possible role of C/EBPd in this pathway, MEFs were starved in serum-free conditions before serum was added back for acute stimulation. As shown in Figure 3A , serum stimulation led to increased phosphorylation of AKT at both Ser473 and Thr308.
Although C/EBPd KO MEFs also exhibited serum-induced AKT phosphorylation, the absolute level of pAKT during serum-starved and stimulated conditions was significantly lower than in WT MEFs. Total AKT protein levels were comparable in WT and KO MEFs. In accordance with reduced AKT activity, serum stimulation of S6K1 phosphorylation was markedly reduced in C/EBPd-deficient MEFs ( Figure 3A ). In addition, 4E-BP1 was hypophosphorylated in KO MEFs, which is indicative for hyperactivity of the repressor. These data demonstrate that C/EBPd KO MEFs are deficient in AKT activity and, consequently, in S6K1 and 4E-BP1 activation, suggesting reduced translational activity.
Phosphorylation of GSK-3b at Ser9 by AKT leads to inactivation of this kinase, which is an inhibitor of the translation initiation factor eIF2B and represses HIF-1a expression (Schnitzer et al, 2005; Proud, 2006) . Consistent with the reduced AKT activity, we found that GSK-3b phosphorylation was decreased in the absence of C/EBPd under serum-stimulated conditions ( Figure 3A) . To further characterize the role of GSK-3b in these cells, we used LiCl, which promotes inhibitory autophosphorylation of GSK-3b (Zhang et al, 2003) . MEFs were treated with DFX in the presence or absence of LiCl or with NaCl as a control. As shown in Figure 3B , LiCl alone did not affect HIF-1a protein expression, but slightly increased the response to DFX. This can be explained by the stimulation of protein translation by LiCl together with inhibition of HIF-1a degradation by DFX. In C/EBPd-deficient cells, LiCl substantially rescued inhibitory Ser9 phosphorylation of GSK-3b and DFX-induced HIF-1a protein accumulation ( Figure 3B ). These data confirm that, consistent with reduced AKT activity, C/EBPd-null MEFs harbour hyperactive GSK-3b, which contributes to the reduced HIF-1a accumulation.
The above analyses suggest that C/EBPd is necessary for AKT/S6K1-mediated activity. To investigate whether this pathway was indeed operating in vivo, we analysed phosphorylation of the ribosomal protein S6, a principal target of S6K1, in mammary tumours. Immunohistochemical analysis showed that S6 phosphorylation was reduced in hypoxic tumour regions ( Figure 3C ), consistent with the notion that general translational activity becomes reduced as a measure of hypoxic adaptation (Kaper et al, 2006) . Nevertheless, it was evident that pS6 staining was less in C/EBPd-null tissue compared with C/EBPd WT tumours ( Figure 3C ). In summary, these data show that C/EBPd promotes ribosomal S6K1 activity in tumour tissue in vivo.
C/EBPd augments HIF-1a expression through stabilization of mTOR protein
Because C/EBPd KO MEFs exhibited reduced Ser473 phosphorylation of AKT, we hypothesized that mTORC2 function may be impaired. Indeed, we found that C/EBPd was necessary for efficient expression of mTOR. C/EBPd-deficient primary MEFs had reduced mTOR protein levels (Supplementary Figure S5A ). Transient expression of mTOR or C/EBPd in C/EBPd-null MEFs reconstituted the mTOR/AKT/ HIF-1 pathway ( Figure 4A ). Exogenous C/EBPd augmented endogenous mTOR and HIF-1a levels, and exogenous mTOR also recovered HIF-1a expression in DFX-treated C/EBPddeficient cells ( Figure 4A ). The mTORC1 complex, which phosphorylates and activates S6K1, is sensitive to inhibition by rapamycin (Dann et al, 2007) . Therefore, we used with shRNA against C/EBPd or GFP as negative control and, 24 h later, was exposed to 1% O 2 , 100 mM DFX or 100 mM CoCl 2 for 16 h. Nuclear extracts were analysed by western analysis, as indicated. (B) U251 glioblastoma cells harbouring an HRE-luciferase reporter were transfected as in A. After 2 days, cells were treated with 100 mM DFX for 16 h followed by western analysis of the indicated proteins. (C) U251 cells were treated as in B and whole cell lysates were analysed for luciferase reporter activity. Reporter activity (mean±s.e.m. of three independent experiments) is shown relative to untreated control samples. *Po0.05. rapamycin to further interrogate the role of mTOR in C/EBPdmediated HIF-1a expression. Rapamycin significantly reduced HIF-1a accumulation in response to DFX in both WT and KO MEFs ( Figure 4B ) and in glioblastoma cell lines under hypoxia (Supplementary Figure S5B) . Similarly, the increase in DFX-induced HIF-1a in KO MEFs after rescue with exogenous C/EBPd was abolished by rapamycin ( Figure 4B) . Collectively, these data show that C/EBPd augments HIF-1a expression through mTORC1. Next, we confirmed that primary mammary tumour cells lacking C/EBPd also exhibited reduced mTOR expression, which was accompanied by decreased phosphorylation of AKT, S6K1 and GSK-3b ( Figure 4C ). The causal relationship of C/EBPd and mTOR expression levels was further confirmed in the MCF-10A human breast epithelial cell line. Depletion of endogenous C/EBPd protein by RNAi resulted in reduced mTOR protein levels ( Figure 4C, bottom panel) . Collectively, these findings show that reduced mTOR protein levels are the reason for an impaired AKT/S6K1 signalling pathway in C/EBPd-null cells that culminates in reduced HIF-1a protein expression. These data are in agreement with the lower levels of HIF-1a protein and HIF-1 target genes in C/EBPd-mutant tumour cells, which are impaired in their glycolytic metabolism and metastatic activity (Figure 1) .
Analysis of mTOR mRNA revealed comparable levels between C/EBPd WT and KO primary MEFs and tumour cells (data not shown), suggesting that C/EBPd regulates mTOR expression post-transcriptionally. The stability of the mTOR protein can be modulated by mechanisms that include ubiquitin-mediated proteasomal degradation (Mao et al, 2008) . Therefore, we assessed the effect of proteasome inhibition by MG132 in primary tumour cells and MEFs, and found that the mTOR protein was stabilized specifically in cells lacking C/EBPd ( Figure 4D ). Next, we examined the ubiquitination status of mTOR after transfection of HA-tagged ubiquitin into WT and KO MEFs. In agreement with reduced mTOR levels, we detected increased mTOR polyubiquitination in C/EBPd-null MEFs compared with WT MEFs ( Figure 4E ). Because mTOR protein stability can be regulated by the tumour suppressor FBXW7 (Mao et al, 2008) , we also assessed expression of this protein. The FBXW7 gene gives rise to three protein isoforms, with the longest a-isoform being predominantly expressed (Welcker and Clurman, 2008) . Consistent with the greater levels of polyubiquitinated mTOR, C/EBPd-null cells contained more FBXW7 protein than WT cells ( Figure 4E ). Moreover, inhibition of protein synthesis confirmed that mTOR protein was degraded more quickly in C/EBPd-deficient MEFs (t 1 2 , B12 h) compared with control cells (t 1 2 , B20 h) ( Figure 4F ). Collectively, these data show that C/EBPd promotes stability of the mTOR protein.
C/EBPd enhances mTOR protein stability through inhibition of FBXW7 expression
As seen in MEFs ( Figure 4E-F) , an inverse correlation of C/EBPd and FBXW7 protein expression was also observed in human MCF-10A, MCF-7 and U251 glioblastoma cell lines. MCF-7 cells expressed more FBXW7 but less C/EBPd (and mTOR), compared with MCF-10A or U251 cells ( Figure 5A ). Overexpression of C/EBPd in MCF-7 cells resulted in downregulation of FBXW7, and mTOR expression was induced as predicted ( Figure 5B ). Moreover, expression of another FBXW7 target, the oncogenic Aurora A kinase (Fujii et al, 2006), was also induced by C/EBPd ( Figure 5B ). This effect was dependent on an intact DNA-binding domain of C/EBPd (Supplementary Figure S6A) . Furthermore, the related proteins C/EBPa and C/EBPb had no effect on FBXW7 protein levels (Supplementary Figure S6A) . Collectively, these data show that C/EBPd downregulates the tumour suppressor FBXW7 and induces expression of its oncogenic targets mTOR and Aurora A.
Because C/EBPd is a transcription factor, we assessed the effect of C/EBPd on FBXW7 mRNA expression. As shown in Figure 5C , C/EBPd KO primary tumour cells contained 3.5-fold increased FBXW7 mRNA levels compared with WT cells. C/EBPd KO MEFs exhibited a more modest but statistically significant two-fold increase. Consistent with these and previous results, FBXW7 protein levels were elevated in C/EBPddeficient cells and associated with reduced mTOR protein expression ( Figure 5C ). The causal relationship of C/EBPd expression and FBXW7 downregulation was further confirmed by RNAi depletion of endogenous C/EBPd protein in MCF-10A and U251 cells, which resulted in increased FBXW7 mRNA and protein levels and concomitantly reduced mTOR protein levels ( Figure 5D and Supplementary Figure S6B) . Analysis of the FBXW7a promoter revealed a potential C/EBP-binding site in the proximal promoter ( Figure 5E ), which was confirmed by electrophoretic mobility shift assay (Supplementary Figure S6C) . ChIP assays with MCF-7 cells demonstrated that endogenous C/EBPd binds to the FBXW7a promoter ( Figure 5E ). Consistent with DFX-induced C/EBPd protein expression in these cells (Figure 2A) , specific binding to the FBXW7a promoter was significantly enhanced after DFX exposure ( Figure 5E ). These results showed that C/EBPd directly binds to the FBXW7a promoter. We then cloned B1.3 kb of the human FBXW7a promoter into a luciferase reporter construct and mutated the C/EBP-binding site. Reporter activity from this construct was inhibited by C/EBPd but not when the C/EBP site was mutated (Supplementary Figure S6D) . Taken together, these results show that C/EBPd directly inhibits FBXW7 gene expression by functioning as a transcriptional repressor.
Recently, it was reported that the viral E1A oncogene inhibits FBXW7 activity (Isobe et al, 2009) . Interestingly, C/EBPd KO MEFs that harbour E1A exhibited normal mTOR levels and DFX-induced HIF-1a expression compared with WT controls, despite elevated FBXW7 expression (Supplementary Figure S7) . To further confirm the causal relationship between FBXW7 inhibition and HIF-1a expression, we silenced FBXW7 expression in C/EBPd-null MEFs. Indeed, this was sufficient to rescue mTOR protein levels and DFX-induced HIF-1a expression in the C/EBPd-deficient cells ( Figure 5F ). Collectively, these data demonstrate that C/EBPd controls mTOR and HIF-1a protein levels through inhibition of FBXW7 expression.
Discussion
In this study, we have found that C/EBPd protects mammary glands from Neu/ERBB2-initiated tumour formation, while on the other hand augmenting metastatic tumour progression. A role of C/EBPd in activation of the CXCR4 gene, which is a known pro-metastatic agent (Gelmini et al, 2008) , may in part contribute to its metastasis-promoting activity. Furthermore, we have shown that C/EBPd is a hypoxia response gene augmenting HIF-1 activity through mTOR stabilization. This is achieved by inhibiting the expression of FBXW7, a tumour suppressor that belongs to the F-box protein family and targets substrates for ubiquitindependent proteasomal degradation. In addition, C/EBPd is an inflammatory response gene activated by STAT3 (Thangaraju et al, 2005) and NF-kB (Litvak et al, 2009 ). The latter also induces HIF-1a at the level of gene transcription (Rius et al, 2008) . Therefore, this study suggests that C/EBPd serves to integrate and amplify hypoxia and inflammatory signalling by promoting the mTOR/AKT/HIF-1 pathway through inhibition of FBXW7 (Figure 6 ). This function within the solid tumour facilitates tumour cell survival and is a plausible explanation for the unexpected pro-metastatic activity of C/EBPd, despite being a tumour suppressor at earlier stages of tumour development. Our data also suggest that clinical application of mTOR inhibitors (Strimpakos et al, 2009 ) may have particular value in the prevention of metastatic disease and in combination with anti-angiogenic agents.
As we employed mice with a germ-line deletion of C/EBPd, we do not rule out the potential contribution of stromal and systemic factors to tumour initiation or metastasis. However, the C/EBPd gene is activated by the STAT3 transcription factor, and loss of STAT3 expression, specifically in Neu/ERBB2 mouse mammary tumours, reduced C/EBPd expression in the epithelial cells and significantly impaired tumour metastasis (Ranger et al, 2009 ). Deletion of HIF-1a from mouse mammary epithelial cells resulted in reduced lung tumour metastases, demonstrating the role of tumour cell intrinsic HIF-1 activity in metastatic progression (Liao et al, 2007) . Furthermore, isolated C/EBPd-deficient tumour cells exhibited reduced expression of not only HIF-1a but also the highly pro-metastatic gene CXCR4. Taken together, these data support a mammary epithelial cell intrinsic role of C/EBPd in metastasis through its role in promoting HIF-1a expression and hypoxic adaptation within the solid tumour.
C/EBPd has been considered a tumour suppressor protein based on (a) growth inhibitory activity in vitro, (b) pro- Figure 6 Model showing how C/EBPd may integrate and amplify hypoxia and inflammatory signals to promote HIF-1a protein expression, hypoxic adaptation and tumour metastasis. Colours indicate effects mediated by regulation of mRNA expression (blue), protein translation (green), protein stability (red) or protein activity (black). The mTOR protein is part of both TORC1 and TORC2 complexes. The dashed line indicates that the mechanism by which hypoxia induces C/EBPd expression remains to be determined. apoptotic activity in vivo, (c) a role in promoting genomic stability, (d) correlation of its expression in tumours with improved patient survival and (e) downregulation of its expression in tumours (see Introduction). This study confirms for the first time the tumour suppressor activity of C/EBPd in an animal model of mammary tumourigenesis. A specific increase in tumour multiplicity of C/EBPd-null mice suggests a protective function early in tumour development. This function may be due to its pro-apoptotic activity in the mammary gland, its role in genome stability and/or its general growth inhibitory properties. Two recent reports from our group provide further mechanisms by which C/EBPd may act as a tumour suppressor. We showed that C/EBPd promotes APC/C-mediated degradation of cyclin D1 by indirectly upregulating Cdc27 expression (Pawar et al, 2010) . Cyclin D1 ablation was shown to protect mice from Neu-mediated mammary tumourigenesis (Yu et al, 2001 ). Yet, C/EBPd-null mammary glands or tumours did not exhibit elevated cyclin D1 expression or reduced expression of Cdc27 (data not shown). However, Cdc27 protein was already barely detectable in C/EBPd WT tissue, perhaps because C/EBPd may not promote Cdc27 expression in these cells. Recently, it was shown that cyclin D1 is required specifically in the mammary stem cells to promote tumourigenesis (Jeselsohn et al, 2010) . Therefore, we can still speculate that an effect of C/EBPd deficiency on cyclin D1 expression in stem cells, which evaded detection by our analyses, may contribute to its role as a tumour suppressor. In addition, we reported that C/EBPd promotes DNA repair by the Fanconi anaemia (FA) pathway by facilitating nuclear translocation of the FANCD2 protein . Mutations in the FA pathway are related to breast cancer risk (Levy-Lahad, 2010) . Furthermore, nuclear localization of FANCD2 is typical of benign breast tumours, and loss of nuclear localization predicts poor outcome for patients (Rudland et al, 2010) . Thus, C/EBPd may act as a tumour suppressor through its role in the FA DNA repair pathway.
The tumour suppressor function of C/EBPd is counterintuitive given its role in mTOR and HIF-1a expression. However, one should bear in mind that C/EBPd is not normally expressed at high levels. Its specific function in HIF-1a expression may be most relevant under acute and particular circumstances such as hypoxic and proinflammatory conditions. On the other hand, although HIF-1a is a wellestablished tumour promoter (Melillo, 2007; Semenza 2010) , some studies also support a tumour suppressor function of HIF-1. In certain cancers, HIF-1 activity can be associated with better patient survival (Semenza, 2003) . In breast cancer patients, diffuse, as opposed to perinecrotic, HIF-1a expression was associated with better survival (Vleugel et al, 2005) . Recent findings suggest that HIF-1 restricts the initial phases of tumour development, as its target mir-210 represses establishment of tumour xenografts (Huang et al, 2009 ). These findings corroborate previous studies, showing that loss of HIF-1a accelerated growth of embryonic stem cell-derived tumours (Carmeliet et al, 1998) or of astrocytoma when grown in blood-vessel-rich brain areas (Blouw et al, 2003) . Furthermore, HIF-1a reduced tumour growth in a renal cell carcinoma xenograft model (Raval et al, 2005) . Several studies highlighted the pivotal function of HIF-1a in cell cycle arrest or apoptosis under hypoxic conditions (Goda et al, 2003; Greijer and van der Wall, 2004; Koshiji et al, 2004) . In this aspect, the function of HIF-1 is reminiscent of that of C/EBPd (Johnson, 2005) . In summary, HIF-1 has differential roles in tumour progression. Under select circumstance, HIF-1 could also function as a tumour suppressor, and it is plausible that C/EBPd may act as a tumour suppressor in part through its role in HIF-1a expression.
Interestingly, our data also revealed a Yin-Yang relationship of C/EBPa and C/EBPd with respect to HIF-1a regulation. C/EBPa inhibits HIF-1 function by competing with HIF1b for direct binding to HIF-1a . In contrast, C/EBPd enhances HIF-1a activity through mTOR-mediated translational regulation. Thus, the two C/EBP family members affect HIF-1 function not only in opposite direction but also by different mechanisms.
Although hypoxia leads to energy deprivation, and energyconsuming processes such as translation are reduced, translation of specific genes such as HIF-1a is induced (Yee Koh et al, 2008) . HIF-1a protein synthesis requires the PI3K/AKT/ mTOR pathway, and defects in this pathway lead to profound attenuation of HIF-1a protein in the majority of cancer cells studied (Abraham, 2004) . Indeed, hypoxia activates the PI3K/AKT/mTOR pathway and promotes HIF-1-dependent survival of various cell types (Yee Koh et al, 2008; Semenza 2010) . In agreement with this, our findings support a significant role of translational activity on HIF-1a accumulation under hypoxic conditions. While oncogenic signals and hypoxia promote HIF-1 function, in part, through stimulating translation, tumour suppressors such as p53, phosphatase and tensin homologue, serine/threonine protein kinase 11 (STK11, LKB1, PJS) and von Hippel-Lindau (pVHL) negatively regulate HIF-1 activity (Semenza, 2003; Yee Koh et al, 2008; Shackelford et al, 2009 ). To our knowledge, C/EBPd is the first tumour suppressor found to promote mTOR and HIF-1 activity.
C/EBPd augments mTOR protein stability by directly inhibiting expression of FBXW7, a subunit of the SKP1/CUL1/ F-box ubiquitin ligase complex that targets many positive regulators of cell cycle for degradation, and, therefore, acts as a tumour suppressor (Welcker and Clurman, 2008) . Inhibition of FBXW7 gene expression by C/EBPd is consistent with its ability to associate with transcriptional co-repressors such as HDAC1 and mSin3A, and with previous reports of target gene repression by C/EBPd (Lacorte et al, 1997; Okazaki et al, 2002; Wang et al, 2006; Lai et al, 2008; Turgeon et al, 2008) . Interestingly, FBXW7 itself is a tumour suppressor (Welcker and Clurman, 2008) , which is consistent with its role in downregulating the mTOR/AKT/HIF-1 pathway. Most FBXW7 targets require 'priming' through phosphorylation by the GSK-3b kinase (Crusio et al, 2010) . Given that loss of C/EBPd leads to hyperactive GSK-3b, (this study and Pawar et al, 2010) , most likely through induction of FBXW7, the pathway also triggers the priming of its substrates. The induction of C/EBPd expression in hypoxic tumour tissue eliminates the FBXW7 break on the mTOR/ AKT/HIF-1, which can explain the pro-metastatic function of C/EBPd.
While this study primarily employed mammary and breast tumour cells, our findings may also be relevant for brain tumours. Loss of FBXW7 expression is an important step in glioma progression (Hagedorn et al, 2007) . In fact, malignant glioblastoma express higher levels of C/EBPd than benign lesions (see http://www.ONCOMINE.org), and our study shows that the U251 glioblastoma cell line depends on C/EBPd for maximal hypoxia-induced HIF-1 activity.
In summary, while we demonstrated the role of C/EBPd as a tumour suppressor in an animal model, our findings also revealed a novel role of C/EBPd in metastasis promotion. Hence, C/EBPd represents a new example of the 'TGF-b paradox' in cancer progression (Tian and Schiemann, 2009) . Our results provide further insight into the mechanisms by which inflammatory and hypoxic signals cooperate to drive tumour progression. The discovery that a tumour suppressor can stimulate the mTOR/AKT/HIF-1 pathway by suppressing another tumour suppressor, FBXW7, reveals novel complexity of this important signalling cascade in cancer.
Materials and methods
Analysis of MMTV-Neu transgenic mice
The MMTV-c-Neu mice (Guy et al, 1992) were crossed with C/EBPdnull mutant mice (Sterneck et al, 1998) on the FVB/NCr genetic background. Female mice were homozygous for MMTV-Neu and derived from intercrosses of C/EBPd heterozygous mice. For the tumour study, mice were monitored twice a week for tumour development and killed with CO 2 when the primary tumour reached B1.5 cm in diameter. At necropsy, gross lesions from all mammary glands and one inguinal mammary gland were fixed in 10% neutralbuffered formalin (NBF). Whole mounts of all mammary glands were fixed in Carnoy's solution and stained with carmine alum. Masses that were at least 4 mm in one dimension and could be confirmed by histological analysis were included in the data. For analysis of metastases, lungs were inflated with 10% NBF, separated lung lobes were paraffin embedded and three 5-mm sections were collected 100 mm apart and stained with hematoxylin and eosin (H and E). NCI-Frederick is accredited by AAALLC International and follows the Public Health Service Policy for the care and use of laboratory animals. Animal care was provided in accordance with the procedures outlined in the 'Guide for Care and Use of Laboratory Animals' (National Research Council; 1996; National Academy Press; Washington, DC).
Statistical analysis
In many analyses, there was a concern that measurements made on clusters of mice with the same parents may be correlated with one another. In the time until tumour analysis, a random effect for these clusters was incorporated into a frailty model survival analysis that was used to compare the tumour hazard rates across the three mouse cohorts: heterozygous, knockout and WT. In the tumour multiplicity analysis, mean tumour counts were compared in a Poisson regression model that included a clusters random effect, and which also included the age of the mouse as an offset. Parameters were estimated using the generalized estimating equations method. For the analysis of the metastasis probabilities, exact conditional inference was used to compare the odds metastasis across the mouse cohorts. Pairwise comparisons of means of continuous measurements were performed using Student's t-tests or Wilcoxon rank-sum tests and a P-value of 0.05 was used to assess statistical significance.
Analysis of metastatic burden
Mice of this model developed few and predominantly intravascular metastases. To assess metastatic burden, H and E-stained lung sections were scanned digitally with the Aperio ScanScope. All metastatic lesions were annotated by the study pathologist. Image analysis was performed using the Aperio Positive Pixel Count macro that was customized to count only the tissue area. The metastatic burden was expressed as the ratio of total area of metastases over total lung area for three sections per lung. An arcsin variance-stabilizing transformation was applied to the metastasis areas, and a two-sample t-test was used to test for homogeneity of metastasis area.
Cell culture and treatments
Primary mammary tumour cells were isolated essentially as described (Varticovski et al, 2007) . Briefly, the tumour tissue was minced by passage through a 40 mm mesh and 18-gauge needle. The cells were collected by centrifugation at 400 r.p.m. for 3 min and cultured in MCF-10A cell medium. Primary MEFs and spontaneously immortalized 3T3 MEFs derived from either WT (C/ebpd þ / þ ) or mutant (C/ebpd À/À ) mice were obtained as described . MEFs and U251/HRE cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) at 371C in a humidified incubator with 5% CO 2 . MCF-7 cells were grown with additional 5 mM sodium pyruvate. MCF-10A cells were cultured in DMEM:F-12 HAM medium, 10% FBS, 10 mg/ml Insulin, 100 ng/ml cholera toxin, 0.5 mg/ml hydrocortisone, 20 ng/ml recombinant epidermal growth factor and 1 mM calcium chloride. Primary MEFs were maintained at 5% O 2 and used at passages 1-4. A 1% O 2 incubator was used as indicated. Cell-culture-grade dimethyl sulfoxide was used as solvent control for MG132 and rapamycin.
Metabolic measurements and cell viability assay
Commercial kits were used to assay extracellular lactate and glucose, as well as cell viability (MTT). See Supplementary Information for details.
Reagents and antibodies
See Supplementary Information for details.
Transient transfections
Cells were seeded 24 h before transfection and co-transfected with C/EBPd or mTOR expression constructs along with a GFP expression construct using Mirus TransIT-LT1 transfection reagent according to manufacturer's instructions. The total amount of DNA in each transfection was kept constant by complementation with vector control DNA. After 24 h, cells were switched to hypoxic treatment as indicated. To silence endogenous C/EBPd, two shRNA expression constructs were used at 1:1 ratio: a pSilencer construct (Wang et al, 2006) and one targeted to the 5 0 region of C/EBPd mRNA with the following sequence 5 0 -GATCCGCAGCAATCACAA GGCGGGCTTCAAGAGAGCCCGCCTTGTGATTGCTGTTTTTTGCTAG CG-3 0 cloned into HindIII/BglII sites in the pSuper vector. FBXW7-specific siRNA (sense: 5 0 -GCACAGAAUUGAUACAACTT-3 0 , antisense: 5 0 -GUUAGUAUCAAUUCUGUGCTG-3 0 ) was purchased from Ambion (Silencers Pre-designed) and nucleofected at a concentration of 100 nM siRNA into 2 Â10 6 cells per 100 ml MEF Nucleofector solution (Amaxa Biosystems/Lonza) according to manufacturer's instructions.
Luciferase reporter assay U251-HRE glioblastoma cells with an integrated luciferase-based HIF reporter (Rapisarda et al, 2002) were transfected and treated as described above. Luciferase activity was assessed using a luciferase assay kit according to manufacturer's instructions (Promega). See Supplementary Information for details on FBXW7 promoter reporter assay.
ChIP assay
The ChIP assay was performed essentially as described (Lin et al, 2010) . See Supplementary Information for details.
Quantitative real-time PCR Total RNA was isolated using TRIZOL (Invitrogen, CA), treated with DNase I and purified by RNAeasy (Qiagen), and cDNA was synthesized using superscript reverse transcriptase III (RT) according to manufacturer's instructions (Invitrogen). PCR was conducted with Taqman gene expression primer/probe sets using the 7500 Fast Real-Time PCR instrument (Applied Biosystems). Analysis was performed using the MxPro Software (Stratagene). All probes were tested in no-RT controls and all reactions were performed in duplicates. The relative expression levels were measured using the relative quantitation DDCt method and normalized to b-actin.
Western analysis
Nuclear extracts were prepared according to methods described previously (Martin et al, 2005) . For whole cell extracts, cells were harvested and washed once with cold PBS and resuspended in 50-100 ml lysis buffer containing 50 mM Tris (pH 8.0), 0.1% NP-40, 400 mM NaCl, 10 mg/ml phosphatase inhibitor I, 10 mg/ml phosphatase inhibitor II and 10 mg/ml protease inhibitor mixture. A measure of 20-50 mg of whole cell extract or 10-20 mg nuclear extract was loaded onto 6 or 10% SDS-polyacrylamide gels. After electrophoresis, proteins were transferred to nitrocellulose membrane and blocked with 5% non-fat dry milk in PBS. Immunoblotting was performed using indicated primary antibodies for overnight incubation at 41C. Following washing and incubation with the appropriate HRP-conjugated secondary antibodies, signals were visualized by enhanced chemiluminescence kit (Pierce, Rockford, IL). Quantification was done by Quantity One software (Bio-Rad). All western analysis data are representative of at least three independent biological replicates.
In vivo ubiquitination and immunoprecipitation studies HA-ubiquitin expression constructs were transfected into MEFs using Mirus transfection reagent. After 24 h, whole cell extracts were prepared and immunoprecipitation was carried out with antimTOR antibodies or IgG as negative control, as described earlier (Pawar et al, 2010) .
Immunohistochemistry
For immunohistochemistry of hypoxia, mice were injected with 1.5 mg pimonidazole 90 min before euthanasia. Tissue was fixed in 10% NBF for o24 h. Primary antibodies were used in the ratio 1:2000 for C/EBPd (Rockland Immunologicals Inc, cat. no. 600-401-A61) after 10 min HIER EDTA antigen retrieval, and in the ratios 1:100 for hypoxyprobe-1 (Natural Pharmacia, HP1-1000) or 1:150 for phospho-S6 (Cell Signaling, cat. no. 2211) after 20 min HIER citrate antigen retrieval.
Supplementary data
Supplementary data are available at The EMBO Journal Online (http://www.embojournal.org).
